Comparing Rapid Micro-Induction and Standard Induction of Buprenorphine/Naloxone for Treatment of Opioid Use Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Opioid Use Disorder
Interventions
DRUG

Buprenorphine/naloxone

Buprenorphine/naloxone is an opioid agonist treatment for opioid use disorder. It is administered via sublingual tablet form.

DRUG

Hydromorphone

Hydromorphone is an opioid used for managing pain, craving, and withdrawal. It is administered orally via tablet or liquid form; or administered intravenously, subcutaneously, or intramuscularly via liquid form.

Trial Locations (1)

V5Z 1M9

RECRUITING

Vancouver General Hospital, Vancouver

All Listed Sponsors
collaborator

Vancouver Coastal Health

OTHER_GOV

lead

University of British Columbia

OTHER